Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

MY-O-SENSES

Financiado

Pre-clinical development of a lentiviral gene therapy to treat hearing and balan...

Pre-clinical development of a lentiviral gene therapy to treat hearing and balance loss in Usher 1B patients The most prevalent genetic sensory defect, sensorineural hearing loss (SNHL), affects >430 million people and results in substantial financial and social consequences. Current treatment options are limited, achieving only temporar... ver más

29/02/2024

MHH

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

MEDIZINISCHE HOCHSCHULE HANNOVER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-29

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

MHH

150.00K€ | Lider

Proyectos interesantes

iHEAR Gene therapy of inherited and acquired hearing loss 2M€ Cerrado

BES-2009-022948 HIPOACUSIAS HEREDITARIAS: INVESTIGACION DE LAS CAUSAS GENETI... 43K€ Cerrado

PID2020-115274RB-I00 BASES GENETICAS Y MOLECULARES DE LA SORDERA NEUROSENSORIAL Y... 266K€ Cerrado

PRE2021-101114 BASES GENETICAS Y MOLECULARES DE LA SORDERA NEUROSENSORIAL Y... 101K€ Cerrado

SAF2008-03216 HIPOACUSIAS HEREDITARIAS: INVESTIGACION DE LAS CAUSAS GENETI... 399K€ Cerrado

SAF2011-24391 INTERACCIONES AMBIENTE-GENOTIPO EN LA PERDIDA AUDITIVA DE DI... 206K€ Cerrado

Últimas noticias

30-11-2024: Cataluña Gestión For... Se ha cerrado la línea de ayuda pública: Gestión Forestal Sostenible para Inversiones Forestales Productivas para el organismo:

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2022-08-08
Fecha Fin: 2024-02-29

Líder del proyecto

MEDIZINISCHE HOCHSCHULE HANNOVER

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto The most prevalent genetic sensory defect, sensorineural hearing loss (SNHL), affects >430 million people and results in substantial financial and social consequences. Current treatment options are limited, achieving only temporary or partial relief and are restricted to a sub-group of patients. Therefore, novel treatment options are of high clinical need. Genetic mutations play a role in the majority of SNHL cases, which makes SNHL an ideal setting for innovative clinical gene therapy approaches. Usher syndrome is an especially severe form of SNHL, with loss of vision and balance accompanying the profound deafness. The size of the underlying genes, mutations of which are causative for Usher syndrome, exceeds the cargo capacity of gene therapy vectors currently employed to treat inner ear disorders. In my ERC-funded consolidator project iHEAR, we have provided the first ground-breaking evidence of efficient gene transfer into inner ear cell types using beyond state-of-the-art lentiviral vectors (LV). As these LV have the capacity to deliver large genetic payloads, we acquired initial data demonstrating functional improvement in a knock-out mouse hearing loss model following LV application. The MY(O)SENSES PoC proposal aims to advance these valuable research results towards clinical application by completing pre-clinical development, securing IP rights and commercializing a formulated medicinal product to launch a first-in-human clinical LV gene therapy trial to treat Usher syndrome patients. This ground-breaking concept can be extended to treat late-onset hearing loss in patients with heterozygous mutations and can be transferred to similar diseases with a genetic or acquired cause. The MY(O)SENSES product will be the first and only treatment that addresses the debilitating vertigo in combination with treating hearing loss in Usher syndrome patients, having the potential to drastically improve patients' lives and benefit society.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores